ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Average Recommendation of “Moderate Buy” from Brokerages

ProQR Therapeutics N.V. (NASDAQ:PRQR) has received a consensus recommendation of “Moderate Buy” from the nine brokerages that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $7.1429.

PRQR has been the subject of a number of recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of ProQR Therapeutics in a research report on Thursday, January 22nd. Zacks Research raised ProQR Therapeutics from a “strong sell” rating to a “hold” rating in a report on Thursday, November 13th.

ProQR Therapeutics Stock Performance

NASDAQ:PRQR opened at $1.78 on Friday. The stock has a 50-day simple moving average of $1.66 and a two-hundred day simple moving average of $2.08. The firm has a market capitalization of $187.27 million, a PE ratio of -3.79 and a beta of 0.21. ProQR Therapeutics has a 52-week low of $1.07 and a 52-week high of $3.10.

Hedge Funds Weigh In On ProQR Therapeutics

Several hedge funds have recently modified their holdings of PRQR. Jane Street Group LLC boosted its position in shares of ProQR Therapeutics by 699.3% during the first quarter. Jane Street Group LLC now owns 91,120 shares of the biopharmaceutical company’s stock worth $121,000 after acquiring an additional 79,720 shares during the last quarter. Sio Capital Management LLC increased its holdings in ProQR Therapeutics by 1.0% in the 2nd quarter. Sio Capital Management LLC now owns 2,075,139 shares of the biopharmaceutical company’s stock valued at $4,233,000 after acquiring an additional 20,546 shares during the last quarter. Walleye Capital LLC lifted its stake in ProQR Therapeutics by 5.6% in the 2nd quarter. Walleye Capital LLC now owns 531,977 shares of the biopharmaceutical company’s stock worth $1,085,000 after purchasing an additional 28,413 shares in the last quarter. Affinity Asset Advisors LLC lifted its stake in ProQR Therapeutics by 6.5% in the 2nd quarter. Affinity Asset Advisors LLC now owns 3,499,512 shares of the biopharmaceutical company’s stock worth $7,139,000 after purchasing an additional 215,000 shares in the last quarter. Finally, Bank of America Corp DE boosted its holdings in shares of ProQR Therapeutics by 25.7% during the 2nd quarter. Bank of America Corp DE now owns 119,198 shares of the biopharmaceutical company’s stock valued at $243,000 after purchasing an additional 24,347 shares during the last quarter. Hedge funds and other institutional investors own 32.65% of the company’s stock.

About ProQR Therapeutics

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.